Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 21/11/2017
SIETES contiene 92130 citas

 
 
 1 a 20 de 163 siguiente >>
Presentar resultados
Seleccionar todas
2. Cita con resumen
Hammann F, Gotta V, Conen K, Medinger M, Cesana P, Rochlitz C, Taegtmeyer AB. Pharmacokinetic interaction between taxanes and amiodarone leading to severe toxicity. Br J Clin Pharmacol 2017;83:927-30. [Ref.ID 101972]
3.Enlace a cita original Cita con resumen
Plessis L, Gómez A, García N, Cereza G, Figueras A. Lack of essential information in spontaneous reports of adverse drug reactions in Catalonia - a restraint to the potentiality for signal detection. Eur J Clin Pharmacol 2017;73:3 de marzo. [Ref.ID 101453]
4. Cita con resumen
Anónimo. Prescribing information sources for healthcare professionals. Drug Ther Bull 2016;54:129-32. [Ref.ID 100943]
5. Cita con resumen
Anónimo. FDA changing advice for prescribing mifepristone. DIA Daily 2016:2. [Ref.ID 100103]
6. Cita con resumen
Anónimo. FDA warns about several safety issues with opioid pain medicines; requires label changes. FDA U.S. Food and Drug Administration 2016:22 de marzo. [Ref.ID 100078]
7.Tiene citas relacionadas Cita con resumen
Bolen SD, Maruthur NM. The safety of incretin based drug treatments for type 2 diabetes. BMJ 2016;352:i801. [Ref.ID 100062]
8. Cita con resumen
Anónimo. Safety information for antipsychotic drug Abilify and risk of certain impulse-control behaviours . Healthy Canadians 2015:2 de noviembre. [Ref.ID 99611]
9. Cita con resumen
Anónimo. Oral diclofenac no longer available OTC. Drug Ther Bull 2015;53:14-7. [Ref.ID 98777]
10. Cita con resumen
Bello AE, Holt RJ. Cardiovascular risk with non-steroidal anti-inflammatory drugs: clinical implications. Drug Saf 2014;37:897-902. [Ref.ID 98405]
11. Cita con resumen
Tan K, Petrie KJ, Faasse K, Bolland MJ, Grey A. Unhelpful information about adverse drug reactions. BMJ 2014;349:g5019. [Ref.ID 98190]
12.Enlace a cita original Cita con resumen
Anónimo. FDA adding general warning to testosterone products about potential for venous blood clots. FDA U.S. Food and Drug Administration 2014:19 de junio. [Ref.ID 97716]
13. Cita con resumen
Tatham KC, Patel KP. Why can't all drugs be vegerarian?. BMJ 2014;348:18-20. [Ref.ID 97253]
14. Cita con resumen
Racoosin JA, Roberson DW, Pacanowski MA, Nielsen DR. New evidence about an old drug - Risk with codeine after adenotonsillectomy. N Engl J Med 2013;368:2155-7. [Ref.ID 95602]
15. Cita con resumen
Anónimo. Magnesium sulfate: drug safety communication - Recommendation against prolonged use in pre-term labor . FDA U.S. Food and Drug Administration 2013:30 de mayo. [Ref.ID 95521]
16. Cita con resumen
Feely MA, Mabry TM, Lohse CM, Sems SA, Mauck KF. Safety of clopidogrel in hip fracture surgery. Mayo Clin Proc 2013;88:149-56. [Ref.ID 95136]
17.Tiene citas relacionadas Cita con resumen
Godlee F. Withdraw approval for Tamiflu until NICE has full data. BMJ 2012;345:27. [Ref.ID 94247]
18. Cita con resumen
Kesselheim AS, Avorn J, Greene JA. Risk, responsibility, and generic drugs. N Engl J Med 2012;367:1679-81. [Ref.ID 93957]
19. Cita con resumen
Anónimo. Getting the timing right. Drug Ther Bull 2012;50:13. [Ref.ID 92424]
20.Enlace a cita original Cita con resumen
Anónimo. Statin drugs - Drug safety communication: class labeling change. FDA U.S. Food and Drug Administration 2012:1 de marzo. [Ref.ID 92196]
Seleccionar todas
 
 1 a 20 de 163 siguiente >>